公开(公告)号：EP3828183A1

公开(公告)日：2021-06-02

申请号：EP19842279.2

申请日：2019-07-25

申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ,  Shouyao Holdings (Beijing) Co., Ltd. ,  Lianyungang Runzhong Pharmaceutical Co., Ltd.

发明人： LI, Jijun ,  ZHU, Yan ,  WANG, Yeliu ,  SHANG, Xianxing ,  WANG, Huting ,  HE, Weinan ,  YAN, Qin ,  SUN, Yinghui ,  ZHANG, Kai ,  LU, Chang ,  XU, Hongjiang ,  TIAN, Xin ,  YANG, Ling

IPC分类号： C07D471/04 ,  C07D487/04 ,  A61K31/437 ,  A61K31/407 ,  A61K31/18 ,  A61P35/00 ,  A61P35/02

摘要： The present invention relates to a sulfoximine compound represented by formula (I) as a bromodomain protein inhibitor and a pharmaceutically acceptable salt thereof and to a preparation method, pharmaceutical composition, and medical use thereof.

公开(公告)号：EP3323817A1

公开(公告)日：2018-05-23

申请号：EP16823908.5

申请日：2016-07-15

申请人： Chia Tai Tianqing Pharmaceutical Group Co.,Ltd ,  Lianyungang Runzhong Pharmaceutical Co., Ltd. ,  Centaurus BioPharma Co., Ltd.

发明人： ZHU, Yan ,  ZHAO, Na ,  SHANG, Xianxing ,  HU, Yuandong ,  PENG, Yong ,  ZHANG, Hui ,  LIU, Bo ,  LUO, Hong ,  HAN, Yongxin ,  YANG, Ling ,  XU, Hongjiang

IPC分类号： C07D403/04 ,  C07D413/04 ,  A61K31/506 ,  A61P35/00 ,  A61P35/02

CPC分类号： C07D403/04 ,  A61K31/506 ,  A61K31/5377 ,  A61P35/00 ,  C07D413/04

摘要： The present disclosure relates to aniline pyrimidine derivatives or pharmaceutically acceptable salts thereof as EGFR inhibitors, specifically relates to compounds represented by formula (I) or pharmaceutically acceptable salts, pharmaceutical compositions, the method and uses thereof for treating EGFR mediated diseases.

公开(公告)号：EP3943496A1

公开(公告)日：2022-01-26

申请号：EP20779433.0

申请日：2020-03-20

申请人： Shouyao Holdings (Beijing) Co., Ltd.

发明人： ZHU, Yan ,  YAO, Jinsuo ,  WANG, Yeliu ,  YAN, Qin ,  HE, Weinan ,  CHEN, Changjun ,  SHANG, Xianxing ,  LI, Jijun ,  SUN, Yinghui ,  LI, Hongjuan ,  LU, Chang ,  ZHANG, Jiuqing ,  HOU, Deng ,  ZHANG, Xiaojun ,  LIU, Qichao

IPC分类号： C07D487/04 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61P35/00

摘要： The present invention relates to a WEE1 inhibitor, and the preparation and use thereof. The WEE1 inhibitor of the present invention is a compound of Formula I or a compound of Formula 11, or a pharmaceutically acceptable salt, solvate, polymorph or tautomer thereof. The present invention also provides use of the WEE1 inhibitor in the manufacture of a medicament for the treatment of a disease associated with WEE1 activity. The WEE1 inhibitor provided by the present invention can effectively treat the disease associated with WEE1 activity.